CSM Advisors LLC Purchases 5,052 Shares of Stryker Corporation $SYK

CSM Advisors LLC lifted its position in shares of Stryker Corporation (NYSE:SYK) by 871.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,632 shares of the medical technology company’s stock after purchasing an additional 5,052 shares during the period. CSM Advisors LLC’s holdings in Stryker were worth $2,081,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC raised its stake in shares of Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after acquiring an additional 609 shares during the last quarter. Schnieders Capital Management LLC. bought a new position in shares of Stryker during the second quarter worth about $205,000. Cetera Investment Advisers boosted its holdings in Stryker by 2.2% in the second quarter. Cetera Investment Advisers now owns 98,966 shares of the medical technology company’s stock valued at $39,154,000 after acquiring an additional 2,169 shares during the last quarter. Intech Investment Management LLC boosted its stake in shares of Stryker by 8.7% in the 2nd quarter. Intech Investment Management LLC now owns 5,977 shares of the medical technology company’s stock valued at $2,365,000 after purchasing an additional 477 shares during the last quarter. Finally, Avantax Advisory Services Inc. lifted its holdings in Stryker by 6.2% in the second quarter. Avantax Advisory Services Inc. now owns 23,629 shares of the medical technology company’s stock valued at $9,348,000 after buying an additional 1,387 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In other news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the completion of the sale, the director owned 2,457,331 shares in the company, valued at $891,814,566.52. This trade represents a 9.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on SYK shares. UBS Group lifted their price objective on Stryker from $386.00 to $400.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 24th. The Goldman Sachs Group set a $399.00 target price on Stryker in a research report on Friday, January 9th. BTIG Research increased their target price on shares of Stryker from $410.00 to $412.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Sanford C. Bernstein raised their price objective on Stryker from $450.00 to $465.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. Finally, Raymond James Financial upgraded shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price objective for the company in a report on Tuesday, January 6th. Fourteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $428.61.

Stryker Trading Up 3.9%

NYSE SYK opened at $349.89 on Tuesday. The business’s fifty day moving average is $365.22 and its 200-day moving average is $367.06. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. The stock has a market capitalization of $133.90 billion, a price-to-earnings ratio of 41.65, a PEG ratio of 1.97 and a beta of 0.85. Stryker Corporation has a one year low of $328.23 and a one year high of $404.87.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The company had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. During the same quarter in the prior year, the business earned $4.01 earnings per share. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. Equities research analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s dividend payout ratio is currently 41.90%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.